Comparative Pharmacology
Head-to-head clinical analysis: NEOSAR versus URACIL MUSTARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSAR versus URACIL MUSTARD.
NEOSAR vs URACIL MUSTARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
Uracil mustard is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
1 mg orally daily for 3 weeks, then 1 mg daily every 4 weeks, or 0.15 mg/kg orally once weekly.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Clinical Note
moderateUracil mustard + Digoxin
"Uracil mustard may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateUracil mustard + Digitoxin
"Uracil mustard may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateUracil mustard + Deslanoside
"Uracil mustard may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateUracil mustard + Acetyldigitoxin
"Uracil mustard may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 6–8 hours in patients with normal renal function; may be prolonged with renal impairment
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Primarily renal (56-80% as unchanged drug and metabolites); minor fecal (10%)
Category C
Category C
Alkylating Agent
Alkylating Agent